Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Genitourinary 1

Conditions

Prostatic Neoplasms 33Ovarian Neoplasms 9Breast Neoplasms 9Pancreatic Neoplasms 8Metastatic Castration-resistant Prostate Cancer 5Carcinoma, Renal Cell 5Urinary Bladder Neoplasms 4Neoplasm Metastasis 4Triple Negative Breast Neoplasms 3Sarcoma 3Lymphoma, Non-Hodgkin 3Endometrial Neoplasms 3Carcinoma, Transitional Cell 3Wilms Tumor 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Prostatic Neoplasms, Castration-Resistant 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Medulloblastoma 2Lung Neoplasms 2Histiocytosis, Langerhans-Cell 2Hereditary Sensory and Autonomic Neuropathies 2Hepatoblastoma 2Glioma 2Ependymoma 2Central Nervous System Neoplasms 2Castration-Resistant Prostate Carcinoma 2Xanthogranuloma, Juvenile 1

Interventions

pembrolizumab 6Radiosurgery 5Docetaxel 5enzalutamide 4darolutamide 3Radiotherapy 3Everolimus 3Androgen Antagonists 3relugolix 2luprolide acetate gel depot 2Surveys and Questionnaires 2Standard of Care 2Radiotherapy, Image-Guided 2Radiofrequency Ablation 2Panobinostat 2Leuprolide 2Abiraterone Acetate 2trastuzumab deruxtecan 1talazoparib 1spartalizumab 1siremadlin 1sipuleucel-T 1sargramostim 1resiquimod 1polysaccharide-K 1poly ICLC 1palbociclib 1olaparib 1liposomal doxorubicin 1ixabepilone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma × olaparib × Genitourinary × Clear all
NCT04556617 2025-04-08

PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Opna Bio LLC

Phase 1/2 Terminated
19 enrolled 11 charts
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡